Media headlines about Kamada (NASDAQ:KMDA) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kamada earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.5125257831126 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern’s scoring:
Shares of KMDA stock traded down $0.05 during mid-day trading on Friday, reaching $4.80. 200 shares of the company’s stock traded hands, compared to its average volume of 21,777. The company has a current ratio of 3.47, a quick ratio of 2.58 and a debt-to-equity ratio of 0.01. The stock has a market cap of $201.31 million, a PE ratio of 26.67 and a beta of 1.17. Kamada has a 12 month low of $4.65 and a 12 month high of $4.85.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.03. The firm had revenue of $17.44 million during the quarter, compared to analyst estimates of $24.89 million. Kamada had a return on equity of 14.64% and a net margin of 11.17%. sell-side analysts forecast that Kamada will post 0.23 earnings per share for the current fiscal year.
Several equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Kamada from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a research report on Friday. ValuEngine cut shares of Kamada from a “sell” rating to a “strong sell” rating in a report on Thursday. TheStreet upgraded shares of Kamada from a “c” rating to a “b” rating in a report on Friday, February 9th. HC Wainwright restated a “buy” rating on shares of Kamada in a report on Thursday, February 8th. Finally, Chardan Capital started coverage on shares of Kamada in a report on Friday, February 2nd. They set a “buy” rating and a $7.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Kamada has an average rating of “Buy” and an average target price of $6.50.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.